PMID- 10569139
OWN - NLM
STAT- MEDLINE
DCOM- 19991202
LR  - 20171206
IS  - 0393-6155 (Print)
IS  - 0393-6155 (Linking)
VI  - 14
IP  - 3
DP  - 1999 Jul-Sep
TI  - Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and 
      their decrease as a predictor of disease control in response to low-dose 
      subcutaneous immunotherapy with interleukin-2.
PG  - 167-71
AB  - Tumor necrosis factor-alpha (TNF-alpha), a cytokine provided by both 
      immunomodulating and inflammatory activities, has been described to be abnormally 
      increased in the blood of patients affected by malignant lymphomas, particularly 
      NHL. However, the biological and clinical significance of TNF-alpha secretion in 
      malignant lymphomas is still controversial. The present study was carried out to 
      further define TNF-alpha secretion in untreated malignant lymphomas and during 
      low-dose IL-2 immunotherapy. The study included 80 malignant lymphoma patients, 
      54 of whom were affected by HD and the other 26 by NHL. The mean TNF-alpha serum 
      concentrations observed in untreated lymphoma patients were significantly higher 
      than those seen in the healthy controls, without significant differences between 
      HD and NHL. Moreover, both HD and NHL lymphoma patients at clinical stage III-IV 
      showed significantly higher mean TNF-alpha levels than those at clinical stage 
      I-II. Finally, patients with systemic symptoms had higher mean TNF-alpha 
      concentrations than those without any systemic symptoms, even though statistical 
      significance was observed only for NHL patients. In a second study we have 
      evaluated changes in TNF-alpha levels in seven evaluable lymphoma patients (NHL: 
      6; HD: 1)--who did not respond to conventional therapies--during subcutaneous 
      low-dose IL-2 (3 MIU/day, 6 days/week for 4 weeks). Long-term stable disease was 
      achieved in four patients with NHL, whereas the other three progressed. In 
      patients with stable disease the mean TNF-alpha concentrations significantly 
      decreased during treatment, whereas they increased in progressing patients. This 
      study, by showing an abnormally enhanced TNF-alpha secretion in both NHL and HD 
      patients with advanced disease and systemic symptoms and a decrease in its levels 
      in patients who achieved disease control on IL-2 immunotherapy, appears to 
      confirm the unfavorable prognostic significance of enhanced TNF-alpha levels in 
      malignant lymphomas.
FAU - Lissoni, P
AU  - Lissoni P
AD  - Division of Radiation Oncology, San Gerardo Hospital, Monza, Italy.
FAU - Bolis, S
AU  - Bolis S
FAU - Mandala, M
AU  - Mandala M
FAU - Viviani, S
AU  - Viviani S
FAU - Pogliani, E
AU  - Pogliani E
FAU - Barni, S
AU  - Barni S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Biol Markers
JT  - The International journal of biological markers
JID - 8712411
RN  - 0 (Interleukin-2)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Interleukin-2/*therapeutic use
MH  - Lymphoma/blood/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Tumor Necrosis Factor-alpha/*analysis
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
PST - ppublish
SO  - Int J Biol Markers. 1999 Jul-Sep;14(3):167-71.